Kura Oncology develops drug therapy for HRAS mutation cancers

October 7, 2016 Christoph Graener

 

Kura Oncology CEO Troy Wilson spoke with Informa Pharma Intelligence at BioPharm America 2016 about his company’s precision medicine approach to treating cancer. Its most advanced drug candidate, tipifarnib, showed promising clinical activity in a Phase II trial in HRAS-expressing solid tumors such as head-and-neck squamous cell carcinoma and salivary gland cancer. He talked about the potential importance of these data because HRAS mutation cancers have no currently approved drug therapy. The La Jolla, Calif.-based company also is working toward filing an IND for a second clinical candidate, an ERK inhibitor, and anticipates selecting a candidate to take forward in Menin-mixed lineage leukemia this year.


Interviewer: Joe Haas – Senior Writer, The Pink Sheet, Informa
Interviewee: Troy Wilson – President, CEO and Co-Founder, Kura Oncology

 

Previous Article
Rentschler maintains continuity while positioning for further growth
Rentschler maintains continuity while positioning for further growth

A leading contract manufacturing organization for the development of biopharmaceuticals, keeping pace with ...

Next Article
CureDuchenne: The Mom Filter scores three profitable exits, one FDA approval
CureDuchenne: The Mom Filter scores three profitable exits, one FDA approval

Debra Miller takes drug development very seriously when it has anything to do with Duchenne muscular dystro...